Analysts Viewpoint
CMPX’s latest rating updates from top analysts.
Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on
Menu
Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on
Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Compass Therapeutics
In a filing, Compass Therapeutics Inc revealed its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0
In a filing, Compass Therapeutics Inc revealed its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0
Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on
In a filing, Compass Therapeutics Inc revealed its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0
Compass Therapeutics Inc’s filing revealed that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0 on
Compass Therapeutics Inc’s recent filing unveils that its CHIEF EXECUTIVE OFFICER Schuetz Thomas J. acquired Company’s shares for reported $21100.0
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its